Unique ID issued by UMIN | UMIN000005250 |
---|---|
Receipt number | R000006242 |
Scientific Title | Efficacy of ezetimibe for the treatment of non-alcoholic fatty liver disease: A randomized, controlled trial |
Date of disclosure of the study information | 2011/03/14 |
Last modified on | 2011/03/14 23:16:32 |
Efficacy of ezetimibe for the treatment of non-alcoholic fatty liver disease: A randomized, controlled trial
Efficacy of ezetimibe for the treatment of non-alcoholic fatty liver disease: A randomized, controlled trial
Efficacy of ezetimibe for the treatment of non-alcoholic fatty liver disease: A randomized, controlled trial
Efficacy of ezetimibe for the treatment of non-alcoholic fatty liver disease: A randomized, controlled trial
Japan |
non-alcoholic fatty liver disease
Hepato-biliary-pancreatic medicine | Endocrinology and Metabolism |
Others
YES
We therefore investigated the efficacy of Ezetimibe treatment for NAFLD patients by an open-label randomized, controlled trial. In this study, we compared the alterations of not only clinical parameters but also histological findings.
Safety,Efficacy
Clinical parameters and liver histologyin NAFLD were evaluated before and after the treatment
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
No treatment
Central registration
2
Treatment
Medicine |
Ezetimibe
control
20 | years-old | <= |
80 | years-old | > |
Male and Female
1) NAFLD in histology
2) dyslipidemia TC 220mg/dl or higher
or treatment to dyslipidemia has already been done.
3) Case it is possible to take ezetimibe about six months
4) Child-Pugh A
5) 20-80 years old age when registering
6) Performance status(ECOG scale) is 0 or 1
7) Key organ function is maintained by clinical examination within 14 days before it registers.
Patients will be excluded from the study if they meet any of the following criteria:
1)hepatic virus infections (hepatitis B and C)
2)the current or past consumption of more than 20 g of alcohol daily
3)concurrent hepatocellular carcinoma, as determined by diagnostic imaging results
4) hepatic encephalopathy
5) active infections
6) severe complication
7) Woman who has possibility of pregnancy or pregnancy or while suckling.
8)Case to whom medicine in which it is using together taboo of ezetimibe and describes attention of using together is administered
9) those who are inadequate for this study as assessed by the investigators
80
1st name | |
Middle name | |
Last name | Eishiro Mizukoshi |
Kananzawa University Graduate School of Medical Science
Department of Disease Control and Homeostasis
13-1 Takara-machi, Kanazawa
076-265-2233
1st name | |
Middle name | |
Last name | Eishiro Mizukoshi |
Kananzawa University Graduate School of Medical Science
Department of Disease Control and Homeostasis
13-1 Takara-machi, Kanazawa
Eishiro Mizukoshi
Kanazawa University Graduate School of Medical Science
Self funding
NO
金沢大学医学部附属病院 (石川県)
2011 | Year | 03 | Month | 14 | Day |
Unpublished
Completed
2008 | Year | 04 | Month | 01 | Day |
2008 | Year | 04 | Month | 01 | Day |
2011 | Year | 02 | Month | 01 | Day |
2011 | Year | 02 | Month | 01 | Day |
2011 | Year | 02 | Month | 01 | Day |
2011 | Year | 02 | Month | 01 | Day |
2011 | Year | 03 | Month | 14 | Day |
2011 | Year | 03 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006242
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |